OR WAIT null SECS
John Docherty, M. Sc., is president and chief operating officer at Helix BioPharma.
July 02, 2009
The authors describe a proprietary process for producing a stable, topical interferon alpha-2b formulation that can deliver large drug molecules into the skin or mucosa.